Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26598263 | 0.92 | KRAS (0.45) | KRAS | |
| SCHEMBL26598179 | 0.90 | KRAS (0.44) | KRAS | |
| SCHEMBL31123128 | 0.84 | KRAS (0.44) | KRAS | |
| SCHEMBL30887768 | 0.83 | KRAS (0.45) | KRAS | |
| SCHEMBL25401732 | 0.80 | KRAS (0.45) | KRAS | |
| SCHEMBL26319508 | 0.80 | KRAS (0.45) | KRAS | |
| SCHEMBL31662295 | 0.80 | KRAS (0.49) | KRAS | |
| SCHEMBL31348395 | 0.80 | KRAS (0.44) | KRAS | |
| SCHEMBL26729251 | 0.80 | KRAS (0.42) | KRAS | |
| SCHEMBL27117610 | 0.79 | KRAS (0.48) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4511127-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20230374036-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374036-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374036-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023205719-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205719-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230339981-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339981-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339981-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339981-A1 | KRAS G12D MODULATING COMPOUNDS | KRAS, NRAS, HRAS | KRAS 1/4885 |
| US-20230374036-A1 | KRAS G12D MODULATING COMPOUNDS | KRAS, NRAS, HRAS | KRAS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.